Foundation (ELF), who provided such outstanding support to concerned respiratory patients
during the pandemic [1].
We feature several chapters on COVID-19 in special populations, reflecting on the impact
during the most difficult periods of the pandemic, and the long-term sequelae relating to airway
diseases [2], ILD [3] and the immunocompromised [4], for example. We review the current state
of the art in therapeutics for COVID-19, in the community [5], in hospital [6] and in the ICU
[7]. The long-term sequelae of COVID-19 have rightly generated a lot of attention, as millions
of patients are living with a complex syndrome arising following COVID-19 infection. Given its
public health importance, we include chapters focussing on the pathophysiology [8] and the
management [9] of long COVID.
We are very grateful to all of our authors, who have contributed their time and effort to making
this such a high-quality Monograph. The COVID-19 pandemic was an unprecedented
disruption to our way of life and to healthcare globally. It is right that we learn every lesson that
we can. The end of the global emergency and the return to normal life for many across the
globe represents a triumph of science and healthcare in developing effective therapies and
vaccines. A further triumph will be learning the lessons of the COVID-19 pandemic to develop
better ways to prevent and treat respiratory viral infections and to avert the next pandemic before
it happens.
We hope all of our readers enjoy the Monograph.
References
1 Williams C. The patient perspective of the pandemic. In: Chalmers JD, Cilloniz C, Cao B, eds. COVID-19:
An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 1–15.
2 Marshall L, Johnson E, Chalmers JD. COVID-19 in patients with airways disease: COPD, asthma and
bronchiectasis. In: Chalmers JD, Cilloniz C, Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield,
European Respiratory Society, 2024 pp. 198–214.
3 Vasarmidi E, Le Guen P, Goletto T, et al. COVID-19 in patients with interstitial lung disease. In: Chalmers JD, Cilloniz
C, Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 215–226.
4 Morrell ED, Mabrey FL, Goodman JS, et al. COVID-19 in the immunocompromised host. In: Chalmers JD, Cilloniz C,
Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 174–197.
5 Liapikou A, Lerikou M. Antiviral therapy for COVID-19. In: Chalmers JD, Cilloniz C, Cao B, eds. COVID-19:
An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 65–78.
6 Roche N, Chalmers JD. Therapeutics in hospitalised adult patients with COVID-19. In: Chalmers JD, Cilloniz C,
Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 104–121.
7 Koulenti D, Almyroudi M-P, Andrianopoulos I, et al. Management of severe COVID-19 in the ICU. In: Chalmers JD,
Cilloniz C, Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 122–152.
8 Boyton RJ, Altmann DM. Long COVID: pathological mechanisms. In: Chalmers JD, Cilloniz C, Cao B, eds.
COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 240–249.
9 Liew F, Openshaw PJM. Long COVID: current management and future prospects. In: Chalmers JD, Cilloniz C,
Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 250–277.
Disclosures: J.D. Chalmers reports receipt of the following, outside the submitted work: grants or contracts from
AstraZeneca, Genentech, Gilead Sciences, GlaxoSmithKline, Insmed, Grifols, Novartis and Boehringer Ingelheim
and consulting fees from AstraZeneca, Chiesi, GlaxoSmithKline, Insmed, Grifols, Novartis, Boehringer Ingelheim,
Pfizer, Janssen, Antabio and Zambon. The remaining authors have nothing to disclose.
https://doi.org/10.1183/2312508X.10012024 ix
during the pandemic [1].
We feature several chapters on COVID-19 in special populations, reflecting on the impact
during the most difficult periods of the pandemic, and the long-term sequelae relating to airway
diseases [2], ILD [3] and the immunocompromised [4], for example. We review the current state
of the art in therapeutics for COVID-19, in the community [5], in hospital [6] and in the ICU
[7]. The long-term sequelae of COVID-19 have rightly generated a lot of attention, as millions
of patients are living with a complex syndrome arising following COVID-19 infection. Given its
public health importance, we include chapters focussing on the pathophysiology [8] and the
management [9] of long COVID.
We are very grateful to all of our authors, who have contributed their time and effort to making
this such a high-quality Monograph. The COVID-19 pandemic was an unprecedented
disruption to our way of life and to healthcare globally. It is right that we learn every lesson that
we can. The end of the global emergency and the return to normal life for many across the
globe represents a triumph of science and healthcare in developing effective therapies and
vaccines. A further triumph will be learning the lessons of the COVID-19 pandemic to develop
better ways to prevent and treat respiratory viral infections and to avert the next pandemic before
it happens.
We hope all of our readers enjoy the Monograph.
References
1 Williams C. The patient perspective of the pandemic. In: Chalmers JD, Cilloniz C, Cao B, eds. COVID-19:
An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 1–15.
2 Marshall L, Johnson E, Chalmers JD. COVID-19 in patients with airways disease: COPD, asthma and
bronchiectasis. In: Chalmers JD, Cilloniz C, Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield,
European Respiratory Society, 2024 pp. 198–214.
3 Vasarmidi E, Le Guen P, Goletto T, et al. COVID-19 in patients with interstitial lung disease. In: Chalmers JD, Cilloniz
C, Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 215–226.
4 Morrell ED, Mabrey FL, Goodman JS, et al. COVID-19 in the immunocompromised host. In: Chalmers JD, Cilloniz C,
Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 174–197.
5 Liapikou A, Lerikou M. Antiviral therapy for COVID-19. In: Chalmers JD, Cilloniz C, Cao B, eds. COVID-19:
An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 65–78.
6 Roche N, Chalmers JD. Therapeutics in hospitalised adult patients with COVID-19. In: Chalmers JD, Cilloniz C,
Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 104–121.
7 Koulenti D, Almyroudi M-P, Andrianopoulos I, et al. Management of severe COVID-19 in the ICU. In: Chalmers JD,
Cilloniz C, Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024
pp. 122–152.
8 Boyton RJ, Altmann DM. Long COVID: pathological mechanisms. In: Chalmers JD, Cilloniz C, Cao B, eds.
COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 240–249.
9 Liew F, Openshaw PJM. Long COVID: current management and future prospects. In: Chalmers JD, Cilloniz C,
Cao B, eds. COVID-19: An Update (ERS Monograph). Sheffield, European Respiratory Society, 2024 pp. 250–277.
Disclosures: J.D. Chalmers reports receipt of the following, outside the submitted work: grants or contracts from
AstraZeneca, Genentech, Gilead Sciences, GlaxoSmithKline, Insmed, Grifols, Novartis and Boehringer Ingelheim
and consulting fees from AstraZeneca, Chiesi, GlaxoSmithKline, Insmed, Grifols, Novartis, Boehringer Ingelheim,
Pfizer, Janssen, Antabio and Zambon. The remaining authors have nothing to disclose.
https://doi.org/10.1183/2312508X.10012024 ix